Trials / Completed
CompletedNCT05371652
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
A Multicenter, Open Label, Long-term Safety Study of BHV3000 for the Acute Treatment of Migraine in Chinese Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 241 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant 75mg Orally Disintegrating Tablets (ODT) | One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack |
Timeline
- Start date
- 2022-05-19
- Primary completion
- 2024-02-06
- Completion
- 2024-02-06
- First posted
- 2022-05-12
- Last updated
- 2025-02-20
- Results posted
- 2025-02-20
Locations
26 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05371652. Inclusion in this directory is not an endorsement.